The 11β-hydroxyandrostenedione pathway and C11-oxy C21 backdoor pathway are active in benign prostatic hyperplasia yielding 11keto-testosterone and 11keto-progesterone

Ho, 2011, Estrogen and androgen signalling in the pathogenesis of BPH, Nat. Rev. Urol., 8, 29, 10.1038/nrurol.2010.207 Kahokehr, 2014, Landmarks in BPH- from aetiology to medical and surgical management, Nat. Rev. Urol., 11, 118, 10.1038/nrurol.2013.318 Marcelli, 1999, Hormonal signaling in prostatic hyperplasia and neoplasia, J. Clin. Endocrinol. Metab., 84, 3463 Andriole, 2004, Dihydrotestosterone and the prostate: the scientific rational for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia, J. Urol., 172, 1399, 10.1097/01.ju.0000139539.94828.29 Vermeulen, 1989, Hormonal effects of an orally active 4-azasteroid inhibitor of 5α-reductase in humans, Prostate, 14, 45, 10.1002/pros.2990140106 McConnell, 1998, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia, N. Engl. J. Med., 338, 557, 10.1056/NEJM199802263380901 Roehrborn, 2010, The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study, Eur. Urol., 57, 123, 10.1016/j.eururo.2009.09.035 American Urological Association, 2014 Payne, 2004, Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones, Endocr. Rev., 25, 947, 10.1210/er.2003-0030 Schloms, 2012, The influence of Aspalathus linearis (Rooibos) and dihydrochalcones on adrenal steroidogenesis: quantification of steroid intermediates and end products in H295R cells, J. Steroid Biochem. Mol. Biol., 128, 128, 10.1016/j.jsbmb.2011.11.003 Rege, 2013, Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation, J. Clin. Endocrinol. Metab., 98, 1182, 10.1210/jc.2012-2912 Pretorius, 2016, 11-Ketotestosterone and 11-ketodihydrotestosterone in castration resistant prostate cancer: potent androgens which can no longer be ignored, PLoS One, 11, 1, 10.1371/journal.pone.0159867 Du Toit, 2017, Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC2-MS/MS quantification of 11β-hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone, J. Steroid Biochem. Mol. Biol., 166, 54, 10.1016/j.jsbmb.2016.06.009 du Toit, 2018, Inefficient UGT-conjugation of adrenal 11β-hydroxyandrostenedione metabolites highlights C11-oxy C19 steroids as the predominant androgens in prostate cancer, Mol. Cell. Endocrinol., 461, 265, 10.1016/j.mce.2017.09.026 Polson, 1988, Serum 11β-hydroxyandrostenedione as an indicator of the source of excess androgen production in women with polycystic ovaries, J. Clin. Endocrinol. Metab., 66, 946, 10.1210/jcem-66-5-946 Carmina, 1992, The ratio of androstenedione: 11β-hydroxyandrostenedione is an important marker of adrenal androgen excess in women, Fertil. Steril., 58, 148, 10.1016/S0015-0282(16)55152-8 Holownia, 1992, Studies to confirm the source of 11β-hydroxyandrostenedione, J. Steroid Biochem. Mol. Biol., 41, 875, 10.1016/0960-0760(92)90441-K Huerta, 1999, 11β-Hydroxyandrostenedione and △5-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylase-deficient nonclassic adrenal hyperplasia, Fertil. Steril., 72, 996, 10.1016/S0015-0282(99)00402-1 Turcu, 2016, Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency, Eur. J. Endocrinol., 174, 601, 10.1530/EJE-15-1181 O’Reilly, 2017, 11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 102, 840, 10.1210/jc.2016-3285 Rege, 2018, 11-Ketotestosterone is the dominant circulating bioactive androgen during normal and premature adrenarche, J. Clin. Endocrinol. Metab., 103, 4589 Nanba, 2019, 11-Oxygenated C19 steroids do not decline with age in women, J. Clin. Endocrinol. Metab., 104, 2615, 10.1210/jc.2018-02527 Yazawa, 2008, Cyp11b1 is induced in the murine gonad by luteinizing hormone/human chorionic gonadotropin and involved in the production of 11-ketotestosterone, a major fish androgen: conservation and evolution of the androgen metabolic pathway, Endocrinol., 149, 1786, 10.1210/en.2007-1015 Storbeck, 2013, 11β-hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?, Mol. Cell. Endocrinol., 377, 135, 10.1016/j.mce.2013.07.006 Bloem, 2015, Advances in the analytical methodologies: profiling steroids in familiar pathways – challenging dogmas, J. Steroid Biochem. Mol. Biol., 153, 80, 10.1016/j.jsbmb.2015.04.009 Campana, 2016, Development of a novel cell based androgen screening model, J. Steroid Biochem. Mol. Biol., 156, 17, 10.1016/j.jsbmb.2015.11.005 Imamichi, 2016, 11-Ketotestosterone is a major androgen produced in human gonads, J. Clin. Endocrinol. Metab., 101, 3582, 10.1210/jc.2016-2311 Choi, 2005, Characterization of testosterone 11β-hydroxylation catalyzed by human liver microsomal cytochromes P450, Drug Metab. Dispos., 33, 714, 10.1124/dmd.104.003327 Swart, 2013, 11β-Hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione, J. Steroid Biochem. Mol. Biol., 138, 132, 10.1016/j.jsbmb.2013.04.010 Gent, 2019, The 11β-hydroxysteroid dehydrogenase isoforms: pivotal catalytic activities yield potent C11-oxy C19 steroids with 11βHSD2 favouring 11-ketotestosterone, 11-ketoandrostenedione and 11-ketoprogesterone biosynthesis, J. Steroid Biochem. Mol. Biol., 189, 116, 10.1016/j.jsbmb.2019.02.013 Van Rooyen, 2018, The in vitro metabolism of 11β-hydroxyprogesterone and 11-ketoprogesterone to 11-ketodihydrotestosterone in the backdoor pathway, J. Steroid Biochem. Mol. Biol., 178, 203, 10.1016/j.jsbmb.2017.12.014 Gent, 2019, 11α-hydroxyprogesterone, a potent 11β-hydroxysteroid dehydrogenase inhibitor, is metabolised by steroid-5α-reductase and cytochrome P450 17α-hydroxylase/17,20-lyase to produce C11α-derivatives of 21-deoxycortisol and 11-hydroxyandrostenedione in vitro, J. Steroid Biochem. Mol. Biol., 191, 10.1016/j.jsbmb.2019.04.018 Barnard, 2017, Adrenal C11-oxy C21 steroids contribute to the C11-oxy C19 steroid pool via the backdoor pathway in the biosynthesis and metabolism of 21-deoxycortisol and 21-deoxycortisone, J. Steroid Biochem. Mol. Biol., 174, 86, 10.1016/j.jsbmb.2017.07.034 McNamara, 2013, Phase two steroid metabolism and its roles in breast and prostate cancer patients, Front. Endocrinol., 4, 1, 10.3389/fendo.2013.00116 Du Toit, 2018, A high-throughput UPC2-MS/MS method for the separation and quantification of C19 and C21 steroids and their C11-oxy steroid metabolites in the classical, alternative, backdoor and 11OHA4 steroid pathways, J. Chromatogr. B, 1080, 71, 10.1016/j.jchromb.2018.02.023 Quanson, 2015 Thomas, 2003, 5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium, J. Urol., 170, 2019, 10.1097/01.ju.0000091804.20183.81 Bauman, 2006, Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer, Endocrinology, 147, 5806, 10.1210/en.2006-0627 Sakai, 2016, De novo steroid biosynthesis in human prostate cell lines and biopsies, Prostate, 76, 575, 10.1002/pros.23146 Rao, 1965, The metabolism of progesterone by animal tissues in vitro, Sex and species differences in conjugate formation during the metabolism of [4-14C]progesterone by liver homogenates, Biochem. J., 96, 172, 10.1042/bj0960172 Kjelf, 1980, Progesterone is conjugated in human urine, Clin. Chim. Acta, 102, 119, 10.1016/0009-8981(80)90024-8 Jin, 1997, The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11, Arch. Biochem. Biophys., 341, 207, 10.1006/abbi.1997.9949 Girard, 2003, Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites, Endocrinology, 144, 2659, 10.1210/en.2002-0052 Kamrath, 2012, Increased activation of the alternative “backdoor” pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis, J. Clin. Endocrinol. Metab., 97, E367, 10.1210/jc.2011-1997 Dhayat, 2018, Urinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary syndrome: a pilot study considering neglected steroid metabolites, PLoS One, 13, 10.1371/journal.pone.0203903 Du Toit, 2018, C11-oxy C19 and C11-oxy C21 steroids in neonates: UPC2-MS/MS quantification of plasma 11β-hydroxyandrostenedione, 11-ketotestosterone and 11-ketoprogesterone, Steroids, 138, 1, 10.1016/j.steroids.2018.06.003 Hayward, 1995, Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1, In Vitro Cell. Dev. Biol., 31, 14, 10.1007/BF02631333 Van der Sluis, 2012, Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer, BJU Int., 109, 176, 10.1111/j.1464-410X.2011.10651.x Hammond, 1978, Serum steroids in normal males and patients with prostatic disease, Clin. Endocrinol. (Oxf.), 9, 113, 10.1111/j.1365-2265.1978.tb02189.x Wurzel, 2007, The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia, Prostate Cancer Prostatic Dis., 10, 149, 10.1038/sj.pcan.4500931 Snaterse, 2017, Circulating steroid hormone variations throughout different stages of prostate cancer, Endocr. Relat. Cancer, 24, R403, 10.1530/ERC-17-0155 Gardi, 1962, Anomalous enolization of 3-keto-5α-steroids, Tetrahedron Lett., 11, 497, 10.1016/S0040-4039(00)70501-6 Kouretas, 1996, Enzymatic conversion of dihydrotestosterone from 3- keto to 3-enol form in the rat prostate, Anticancer Res., 16, 2843 Drmanovic, 1999, Albumin possesses intrinsic enolase activity towards dihydrotestosterone which can differentiate benign from malignant breast tumors, Anticancer Res., 19, 4113 Sinclair, 2005, Metabolism of the 16-androstene steroids in primary cultured porcine hepatocytes, J. Steroid Biochem. Mol. Biol., 96, 79, 10.1016/j.jsbmb.2005.01.030 Sinclair, 2005, Synthesis of free and sulphoconjugated 16-androstene steroids by the Leydig cells of the mature domestic boar, J. Steroid Biochem. Mol. Biol., 96, 217, 10.1016/j.jsbmb.2005.02.017 Kjeld, 1980, Progesterone is conjugated in human urine, Clin. Chim. Acta, 102, 119, 10.1016/0009-8981(80)90024-8 Brolin, 1992, Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue, Prostate, 20, 281, 10.1002/pros.2990200404 Hiramatsu, 1996, Immunolocalization of oestrogen and progesterone receptors in prostatic hyperplasia and carcinoma, Histopathology, 28, 163, 10.1046/j.1365-2559.1996.280326.x Song, 2016, Differential expression of androgen, estrogen and progesterone receptors in benign prostatic hyperplasia, Bosn. J. Basic Med. Sci., 16, 201, 10.17305/bjbms.2016.1209 Chen, 2017, Progesterone receptor in the prostate: a potential suppressor for benign prostatic hyperplasia and prostate cancer, J. Steroid Biochem. Mol. Biol., 166, 91, 10.1016/j.jsbmb.2016.04.008 Grindstad, 2018, Progesterone receptors in prostate cancer: progesterone receptor B is the isoform associated with disease progression, Sci. Rep., 8, 1 Muthusamy, 2011, Estrogen receptor β and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer, Proc. Natl. Acad. Sci., 108, 20090, 10.1073/pnas.1117772108